期刊
SCIENCE
卷 348, 期 6230, 页码 56-61出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.aaa8172
关键词
-
资金
- PCF Challenge Grant in Immunology
- NCI/NIH [1-R01 CA1633793-01]
- Cancer Prevention Research in Texas grants
- Stand Up To Cancer-Cancer Research Institute Cancer Immunology Dream Team Translational Cancer Research Grant
Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, has led to important clinical advances and provided a new weapon against cancer. This therapy has elicited durable clinical responses and, in a fraction of patients, long-term remissions where patients exhibit no clinical signs of cancer for many years. The way forward for this class of novel agents lies in our ability to understand human immune responses in the tumor microenvironment. This will provide valuable information regarding the dynamic nature of the immune response and regulation of additional pathways that will need to be targeted through combination therapies to provide survival benefit for greater numbers of patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据